As covered by Fairfax Times, Novo Nordisk has reported encouraging long-term findings for its investigational hemophilia A therapy denecimig (Mim8), with interim results from the Phase 3 FRONTIER4 extension study showing sustained efficacy and a favorable safety profile across multiple dosing schedules. The data were presented at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris.
Denecimig is a subcutaneous factor VIIIa-mimetic antibody currently under review by the U.S. Food and Drug Administration (FDA). The therapy is being developed for people with hemophilia A, regardless of whether they have factor VIII inhibitors.
FRONTIER4 Demonstrates Durable Bleed Protection
The open-label FRONTIER4 extension trial evaluated long-term prophylactic treatment with denecimig in 426 participants aged 1 year and older, including both pediatric and adult populations. Participants received treatment using one of three dosing regimens: weekly, every two weeks, or once monthly.
Safety findings remained consistent with previous studies in the FRONTIER clinical program. Injection-site reactions occurred infrequently, affecting approximately 2.0% of injections in children and 1.8% in adolescents and adults. Reported reactions were mild and temporary, and investigators found no clinical evidence of neutralizing antibodies.
Efficacy outcomes also remained strong over time. Estimated mean annualized bleeding rates (ABRs) were 0.75 among adolescents and adults and 0.37 among children. Notably, about 71% of adult and adolescent participants and 89% of pediatric participants experienced no treated bleeding episodes while receiving denecimig prophylaxis.
Patient-Reported Outcomes Highlight Reduced Treatment Burden
Exploratory analyses of patient-reported outcomes suggested sustained benefits beyond bleed prevention. Individuals aged 12 years and older reported improvements in joint pain, while participants across age groups described lower treatment burden compared with previous experiences.
Usability assessments also indicated high levels of satisfaction with the denecimig pen-injector. Among 185 respondents, more than 94% rated the device as easy or very easy to use, and nearly 90% considered the preparation and injection process quick or very quick.
Thrombin Generation Findings Add Mechanistic Support
Additional post hoc analyses from the Phase 3 FRONTIER2 and FRONTIER5 studies examined thrombin generation in participants aged 12 years and older. Researchers found that denecimig increased thrombin generation into normal reference ranges without evidence of excessive clotting activity. These findings further support the therapy’s mechanism of action and reinforce results observed throughout the broader clinical development program.
Regulatory Review Underway
Novo Nordisk submitted a Biologics License Application (BLA) for denecimig to the FDA in September 2025. The latest data are expected to contribute to the growing body of evidence supporting its potential use as a preventative treatment option for a wide range of patients with hemophilia A.
Clinical experts noted that long-term efficacy and flexible dosing schedules are particularly important in chronic bleeding disorders, where treatment adherence and lifestyle considerations can significantly influence outcomes.
Concizumab Data Show Benefits in Children With Inhibitors
Alongside the denecimig presentation, Novo Nordisk also shared new Phase 3 explorer10 trial results for concizumab in children younger than 12 years with hemophilia A or B who have inhibitors.
The study enrolled 24 patients and compared outcomes during concizumab prophylaxis with prior on-demand treatment. Investigators reported a mean ABR of 2.08 during prophylaxis, compared with 11.51 during previous on-demand management, corresponding to an estimated 82% reduction in bleeding rates.
Most adverse events were mild and resolved during the study. Injection-site reactions were uncommon, although serious adverse events were reported in 29% of participants. Overall, the safety findings were considered manageable and consistent with prior experience with the therapy.
Outlook
The latest ISTH 2026 presentations strengthen the clinical evidence supporting denecimig as a potential new prophylactic option for hemophilia A. With low bleeding rates, a favorable long-term safety profile, and multiple dosing frequency options, the investigational therapy could offer greater flexibility for both children and adults if approved. Meanwhile, new pediatric data for concizumab further expand Novo Nordisk’s growing portfolio of therapies aimed at addressing unmet needs in hemophilia care.
